Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23147167 | 0.83 | KDM4E (0.46) | MAPK14ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL25529134 | 0.78 | L3MBTL1 (0.38) | MAPK14ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL30174170 | 0.78 | MYC (0.36) | MAPK14ALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL25227025 | 0.78 | MYC (0.36) | MAPK14ALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL30174285 | 0.77 | KDM4E (0.36) | MAPK14ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL25533451 | 0.75 | KDM4E (0.40) | MAPK14ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL30063313 | 0.75 | KDM4E (0.40) | MAPK14ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL30174302 | 0.74 | MAPK14 (0.34) | MAPK14ALDH1A1L3MBTL1KDM4EGPR119 | |
| SCHEMBL25529138 | 0.74 | MAPK14 (0.34) | MAPK14ALDH1A1L3MBTL1KDM4EGPR119 | |
| SCHEMBL25529152 | 0.72 | TYK2 (0.35) | MAPK14ALDH1A1NPC1RAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | MAPK14 307/4885ALDH1A1 3998/4885L3MBTL1 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.